Janux Therapeutics disclosed a new data cut from its Phase 1 study of JANX007, a T‑cell engager for prostate cancer, showing a 30% objective response rate in the evaluated cohort. The company presented early safety and efficacy signals for a solid‑tumor TCE—an area where on‑target, off‑tumor toxicity and limited penetration have constrained progress. Janux said the findings will guide dose escalation and indicate potential for further development in prostate malignancies, while emphasizing the need for follow‑up data and expanded cohorts.